Lupin Pharmaceuticals, Inc.’s Abbreviated New Drug Application (ANDA) for Quinapril Tablets USP in 5 mg, 10 mg, 20 mg and 40 mg strengths has recently received final approval from the USFDA.
A product for the treatment of hypertension, Lupin's Quinapril Tablets USP are the AB-rated generic equivalent of Pfizer's Accupril® Tablets.
This approval is Lupin's 13th ANDA approved by the USFDA to date and the third in its fiscal year.
wholly owned subsidiary of Lupin Limited, Lupin Pharmaceuticals, Inc. (among the top six Pharmaceutical companies in India) is dedicated to delivering high-quality, affordable generic medicines trusted by healthcare professionals and patients across geographies.
Download file (pdf) so you can read the full press release.
Comment Preview